Rituximab Therapy in Refractory Adult and Juvenile Idiopathic Inflammatory Myopathy (IIM)

Trial Profile

Rituximab Therapy in Refractory Adult and Juvenile Idiopathic Inflammatory Myopathy (IIM)

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Rituximab (Primary)
  • Indications Dermatomyositis; Polymyositis
  • Focus Biomarker; Therapeutic Use
  • Acronyms RIM
  • Most Recent Events

    • 21 Oct 2014 New source identified and integrated (ClinicalTrials.gov record: NCT00106184)
    • 21 Oct 2014 New source identified and integrated (ClinicalTrials.gov record: NCT00106184)
    • 20 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top